pump and dump cycle

This is certainly good news for Relenza. However it also revealed GSK is a drag to Relenza sales in addition to the idiotic board.

Quote:

" Dallas County health authorities say flu is on track to peak within the next few weeks. But, many people diagnosed with the virus, may be forced to go without treatment. Doctors say Tamiflu pills - the most commonly prescribed flu treatment - aren't effective against this year's most prevalent strain.
The alternative anti-viral drug, Relenza, is now in short supply in some places”

Read the Miso’s full post at:
http://www.hotcopper.com.au/post_single.asp?fid=1&tid=819992&msgid=4543615

Japan like Dallas probably has the same Northern hemisphere flu cycle. And GSK could only supply 0.4m packs in Feb and 0.6m packs in Mar. Just like during the pandemic stockpile, GSK need to be dragged out of bed by governments threats to breach patent protection laws. And by the time GSK is dragged out of bed, the flu season is close to over. During the pandemic stock pile GSK was forced to increase capacity to 100 of millions of courses. Since the cozy cooked deal, production capacity dwindled and GSK is more interested to sell Relenza options and pandemic flu.

The half yearly result will be out soon. And is this another pump and dump cycle? Have we see another repeat of the UK order good news followed by the GSK sales report. Is this good news preceding the BTA half year report?

Read this article if you have doubts on GSK’s best effort.
http://www.chinadaily.com.cn/bizchina/2009-02/06/content_7450505.htm